Genocea Biosciences (GNCA) Tops Q4 EPS by 12c; Announces Diantha Duvall as New CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Biosciences (GNCA) PT Lowered to $2 at Needham & Company
March 1, 2019 8:01 AM ESTNeedham & Company analyst Chad Messer lowered the price target on Genocea Biosciences (NASDAQ: GNCA) to $2.00 (from $3.00) while maintaining a Buy rating.
Messer commetned, "Genocea ended 2018 with $26.4M. On February 12th the company announced a flexible private placement adding up to $39.2M to the... More
Genocea Biosciences (GNCA) PT Raised to $5.75 at H.C. Wainwright
February 28, 2019 11:55 AM ESTH.C. Wainwright analyst Joseph Pantginis raised the price target on Genocea Biosciences (NASDAQ: GNCA) to $5.75 (from $5.00) while maintaining a Buy rating following results.
Pantginis said the initial immunogenicity data of GEN-009 remains key catalyst for shares.
"Readout of... More
